Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NiproNPRRF 72 EV-to-EBIT is 21.18 as of Aug. 05, 2026, which is 26% below its 10-year median of 28.48. GuruFocus rates NPRRF with a GF Score™ of 72/100 and a GF Value™ of $9.30. The stock has 6 warning signs investors should review. Among 470 Medical Devices & Instruments companies, Nipro ranks worse than 59.36% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Nipro's Enterprise Value is $5,480 Mil.
Nipro's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $259 Mil. Therefore, Nipro's EV-to-EBIT for today is 21.18.
The historical rank and industry rank for Nipro's EV-to-EBIT or its related term are showing as below:
NPRRF'
s EV-to-EBIT Range Over the Past 10 Years
Min: -121.56 Med: 28.48 Max: 67.44
Current: 21.91
During the past 13 years, the highest EV-to-EBIT of Nipro was 67.44. The lowest was -121.56. And the median was 28.48.
NPRRF's EV-to-EBIT is ranked worse than 59.36% of 470
companies
in the Medical Devices & Instruments industry
Industry Median: 19.07
vs NPRRF: 21.91
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Nipro's Enterprise Value for the quarter that ended in Mar. 2026 was $5,430 Mil.
Nipro's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $259 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nipro EV-to-EBIT Related Terms
Nipro EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Nipro's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Nipro's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nipro EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nipro's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Nipro's EV-to-EBIT falls into.
Nipro's current Enterprise Value is $5,480 Mil.
Nipro's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $259 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nipro (NPRRF) has a EV-to-EBIT of 21.18 as of Aug. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Nipro and its competitors. This is 26% below median its historical median of 28.48. According to the industry distribution chart, Nipro ranks #279 out of 470 companies in the Medical Devices & Instruments industry, placing it in the top 59.4%.
Is Nipro's EV-to-EBIT too high?
Nipro's current EV-to-EBIT of 21.18 is 26% below median its 10-year median of 28.48. The Medical Devices & Instruments industry median EV-to-EBIT is 19.07. Nipro's value of 21.18 is 11.1% above this industry median. Based on the distribution chart, Nipro ranks #279 out of 470 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Nipro has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Nipro's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nipro ranks #279 out of 470 companies for EV-to-EBIT. This places Nipro in the lower half of its industry. The industry median EV-to-EBIT is 19.07. Nipro's value of 21.18 is 11.1% above this benchmark. While the company's 10-year median is 28.48 vs. the industry median of 19.07, Nipro has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.07, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nipro's current EV-to-EBIT of 21.18 is 11.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Nipro and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nipro's current EV-to-EBIT is 21.18, which is 26% below median its own 10-year median of 28.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nipro stock overvalued right now?
Nipro (NPRRF) has a current EV-to-EBIT of 21.18. The stock's GF Value™ is $9.30, compared to a current price of $9.96 — trading 7.1% above its estimated fair value. The current EV-to-EBIT is 21.18, which is 26% below median its 10-year median of 28.48 and 11.1% above the Medical Devices & Instruments industry median of 19.07. Nipro's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Nipro (NPRRF), the current EV-to-EBIT is 21.18 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nipro (NPRRF) Overvalued in 2026?
Based on GuruFocus' analysis, Nipro stock appears to be overvalued.
The current stock price of $9.96 is trading 7.1% above its estimated GF Value™ of $9.30.
Key valuation signals for NPRRF:
EV-to-EBIT: 21.18 (26% below median its 10-year median of 28.48)
GF Value™: $9.30 vs. price of $9.96 (7.1% above fair value)
Industry Position: 11.1% above the Medical Devices & Instruments median (#279 of 470)
No single metric tells the full story. See the NPRRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.
72GF Score
Get the complete analysis for NPRRF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NPRRF has been successfully added to your 
